論著(zhù)
靜脈丙種球蛋白治療川崎病療效觀(guān)察
吳永忠 李肽芝
【摘要】 目的 探討不同用法靜脈輸注丙種球蛋白（IVIG）治療小兒川崎病的臨床療效。方法 對298例川崎?。↘D）患兒采用3種不同治療方案：A組為IVIG 1g/kg單次靜脈輸注；B組為IVIG 2.0g/kg單次靜脈輸注，C組為IVIG 0.4g/（kg?d）， 連用4～5d，對比3組治療后冠狀動(dòng)脈病變(CAD)發(fā)生率和急性期臨床癥狀消失時(shí)間。
【關(guān)鍵字】 黏膜皮膚淋巴結綜合征,免疫球蛋白類(lèi),冠狀動(dòng)脈病變
中圖分類(lèi)號：R725.4文獻標識碼：B文章編號：1671-8194（2011）01-0035-02
Analysis of Treating Kawasaki Disease with Intravenous Immunoglobulin
WU Yong-zhong, LI Tai-zhi
Department of Pediatrics, Taojiang People's Hospital, Taojiang 413400, China
[Abstract] Objective To explore the clinical effect of treating Kawasaki disease with different IVIG dosage. Method 298 patients were divided into 3 groups with different dosage for the treatment: the dosage of Group A was IVIG 1g/kg only once, the dosage of Group B was IVIG 0.4g/（kg·d） everyday, lasting 4～5 days. the dosage of Group C was IVIG 2.0g/（kg·d） only once. Result CAD was effectively prevented by either 1g/kg or only 2.0g/kg or 0.4g/（kg·d）(lasting 4～5 days) of IVIG within 10 days after the onset of the illness. On the remission of acute phrase symptoms, the regimen of 1g/kg or 2.0g/kg IVIG was obviously better than the one of 0.4g/ （kg·d） IVIG, But the group of A and C was not obviously better . Conclusion 1g/kg IVIG is an effective and economic dosage for the treatment of Kawasaki disease.
川崎病又稱(chēng)黏膜皮膚淋巴結綜合征，是小兒后天獲得性心臟病的重要病因之一，靜脈丙球治療川崎病防止冠狀動(dòng)脈病變已得到肯定，但如何應用靜脈丙球，既安全經(jīng)濟又要有效，一直是兒科探討的問(wèn)題。
